Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare a combination of hyaluronic acid and
chondroitin sulfate (V0220) to Hyalgan® on pain relief in patients with symptomatic knee
osteoarthritis (OA) over 24 weeks when administered in three weekly injections.
Chondroitin sulfate is one of the components of cartilage. Studies have shown that
chondroitin sulphate improves the quality of the hyaluronic acid produced in the joint. The
benefit of V0220 combination is based on two main physicochemical properties, in line with
the characteristics of osteoarthritic disease: optimising the rheological behaviour and
improving the buffering effect on synovial flow ("outflow buffering").